Skip to main content

Table 2 IC50 of Sorafenib and nanaomycin in Hep3B naïve cells and Hep3Bresistant cells

From: DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation

Drugs (μM)

Inhibitory concentration, IC50 (μM)

Hep3B naive cells

Hep3B resistant cells

Sorafenib

9.56 ± 1.77

15.7 ± 3.11

Nanaomycin

5.56 ± 3.19

7.48 ± 5.92

Sorafenib + Nanaomycin 2

6.38 ± 0.81

7.71 ± 0.88

Sorafenib + Nanaomycin 5

3.01 ± 0.75

4.68 ± 0.95

Sorafenib + Nanaomycin 10

1.42 ± 0.20

2.06 ± 0.43